X-linked Lymphoproliferative Disease (XLP)
A rare inherited immune disorder that leaves boys vulnerable to overwhelming immune reactions to Epstein-Barr virus, including life-threatening hemophagocytic lymphohistiocytosis and lymphoma.
- EBV-triggered HLH risk
- Genetic confirmation available
- Stem cell transplant curative option
- Inheritance
- X-linked recessive
- Primarily Affects
- Boys, typically before age 10
- Key Trigger
- Epstein-Barr virus (EBV) infection
- Advanced Therapies
- Allogeneic stem cell transplant
Condition Overview
X-linked lymphoproliferative disease (XLP) is a rare, inherited disorder of the immune system caused by mutations in genes that normally help regulate how immune cells respond to infection. Because the gene sits on the X chromosome, XLP almost always affects boys, who inherit a single non-working copy from their mother.
The hallmark of XLP is an inability to control the immune response to Epstein-Barr virus (EBV), a very common childhood infection that is usually mild. In a child with XLP, EBV infection can trigger an uncontrolled, body-wide immune overreaction called hemophagocytic lymphohistiocytosis (HLH), which can be fatal without rapid treatment. Other children with XLP instead develop low antibody levels, recurrent infections, or lymphoma, even without a clear EBV trigger.
Because the first serious episode can be life-threatening, early recognition — ideally before a triggering infection occurs, such as in a family with a known history — and prompt access to specialist immunology and hematology care are central to improving outcomes.
Types and Subtypes
XLP is divided into two genetically distinct but clinically overlapping forms.
Symptoms and Signs
Symptoms can appear suddenly, often during or shortly after a viral illness, or develop more gradually as recurrent infections or low blood counts.
Causes and Risk Factors
XLP is caused by an inherited gene change rather than anything a parent did during pregnancy.
Diagnosis and Investigations
Diagnosis combines clinical suspicion, immune function testing, and confirmatory genetic analysis.
Disease Course and Risk Stratification
XLP does not use a tumor staging system. Instead, children are stratified by clinical course and complication risk, which guides how closely they are monitored and whether transplant is recommended.
Standard Treatment Options
Treatment is tailored to whether a child is in an acute crisis, has chronic symptoms, or is being monitored after a genetic diagnosis.
Advanced and Emerging Therapies
Beyond transplant, several newer approaches are being explored to control inflammation and restore immune balance.
Cellular Therapy
Reduced-intensity conditioning stem cell transplant
Lower-intensity conditioning regimens aim to achieve the same curative immune reconstitution with fewer transplant-related complications, an active area of pediatric transplant research.
Targeted Immunomodulation
Cytokine-directed therapies (e.g., emapalumab)
Therapies targeting interferon-gamma signaling are being used and studied to control HLH-related hyperinflammation, particularly when first-line therapy is insufficient.
Gene Therapy
Investigational gene-corrective approaches
Early gene therapy strategies for primary immunodeficiencies are an active research area; applicability to XLP specifically remains investigational.
Biomarkers & Precision Medicine
Specific molecular findings help confirm the diagnosis and anticipate the likely disease pattern.
When to Seek 2nd Opinion
Because XLP is rare and decisions around transplant timing carry significant weight, a second opinion from a center experienced in primary immunodeficiency can be valuable.
Clinical Trials and Research
Prognosis & Outcomes
Outcomes in XLP vary considerably depending on whether the diagnosis is made before or after a severe complication occurs, and whether stem cell transplant is pursued.
Supportive Care
Ongoing supportive measures help reduce complications and support quality of life for boys living with XLP.
How CancerFax Helps You Explore Treatment Options
CancerFax helps families of children with XLP access specialist immunology review of genetic and immune test results, coordinate second opinions on transplant timing, and connect with experienced pediatric transplant centers, including across borders when needed.
Get a free case reviewFrequently Asked Questions
XLP is a rare inherited immune disorder, caused by mutations in the SH2D1A or XIAP genes, that impairs the body's ability to control its immune response to Epstein-Barr virus infection, leading to risks of severe inflammation (HLH), recurrent infections, and lymphoma.
The genes responsible for XLP are located on the X chromosome. Boys have only one X chromosome, so a single altered copy causes disease, while girls usually have a working second copy and are typically unaffected carriers.
Epstein-Barr virus (EBV) infection is the most common trigger for severe disease, particularly hemophagocytic lymphohistiocytosis (HLH), though some complications can occur without an identified trigger.
Allogeneic stem cell transplant can correct the underlying immune defect and is considered a potentially curative option for many children with XLP, particularly when performed before severe complications occur.
Diagnosis combines immune function testing, such as SAP or XIAP protein expression studies, with genetic sequencing of the SH2D1A or XIAP genes to confirm the specific mutation.
Yes. In families with a known history of XLP, genetic testing of at-risk male relatives can identify the condition before symptoms develop, allowing proactive monitoring and earlier consideration of transplant.
XLP1 (SH2D1A/SAP deficiency) is more associated with lymphoma and low antibody levels, while XLP2 (XIAP deficiency) is more associated with recurrent HLH and inflammatory bowel disease, though both can overlap clinically.
HLH is an uncontrolled immune and inflammatory reaction causing persistent fever, an enlarged spleen, falling blood counts, and organ dysfunction. It requires urgent hospital-based treatment.
Most female carriers are asymptomatic because they have a working copy of the gene, though genetic counseling is recommended to understand individual risk and inform family planning.
Yes. CancerFax can help families review medical reports and genetic test results, coordinate second opinions on transplant timing and donor options, and connect with experienced pediatric immunology and transplant centers, including cross-border coordination where needed.
Get Expert Guidance for XLP
Send your child's genetic and immune test results for specialist review, or request a second opinion on transplant timing.